natgillin/translations-raw huggingface dataset:
In ovarian, fallopian tube and peritoneal cancer, two main studies were performed involving 3,401 patients with newly diagnosed cancer including advanced cancer.
V zvezi z rakom jajčnikov, jajcevodov ali potrebušnice so izvedli dve glavni študiji, ki sta vključevali 3 401 bolnika z na novo diagnosticiranim rakavim obolenjem, vključno z napredovalim rakom.
In overdose you may notice sweating, tremor (minor shaking), confusion, amnesia (memory loss) and seizure (fits).
V primerih prevelikega odmerjanja lahko opazite potenje, drhtavico (blago tresenje), zmedenost, amnezijo (izgubo spomina) in epileptične napade (krče).
In paediatric and adult patients with Sickle Cell Syndrome the systemic exposure to hydroxycarbamide at steady state was similar by means of the area under the curve.
Pri pediatričnih in odraslih bolnikih s srpasto celičnim sindromom je bila izpostavljenost hidroksikarbamidu, pri vzpostavljenem ravnotežju zdravila, po površini pod krivuljo podobna.
In paediatric clinical studies, a single intravenous (IV) dose of 40 mg/kg up to a maximum of 2 g did not result in toxicity.
V kliničnih študijah pri otrocih pri enem intravenskem (i.v.) odmerku 40 mg/kg do največ 2 g ni prišlo do toksičnega učinka.
In paediatric clinical trials of aripiprazole akathisia and parkinsonism were observed.
Pri kliničnih študijah aripiprazola pri pediatričnih bolnikih so opazili pojav akatizije in parkinsonizma.
In paediatric CML patients the most frequent toxicities observed were grade 3 or
Pri pediatričnih bolnikih s KML so izmed toksičnih učinkov najpogosteje opažali citopenije 3.
In paediatric liver and kidney transplant patients, values for total body clearance of
Pri pediatričnih bolnikih z jetrnim presadkom je bila vrednost celokupnega telesnega očistka
In paediatric patients (12 months to 17 years of age), dosing should be based on the patient’s body surface area (see Instructions for Use in Paediatric Patients, Mosteller1 Formula).
Pri pediatričnih bolnikih (starih od 12 mesecev do 17 let) je treba odmerjanje določiti glede na bolnikovo telesno površino (glejte Navodila za uporabo pri pediatričnih bolnikih, Mostellerjeva1 formula).
In paediatric patients (aged 6 years and above), efficacy has been demonstrated with zonisamide in a double-blind, placebo-controlled study, which included 207 subjects and had a treatment duration of up to 24 weeks.
Pri pediatričnih bolnikih (starih 6 let in več) so učinkovitost dokazali v dvojno slepi, s placebom kontrolirani študiji z zonisamidom, v katero je bilo vključenih 207 bolnikov, ki se je zdravilo do 24 tednov.
In paediatric patients <7 yrs of age, 0/7 male patients tested positive for IgG anti-agalsidase alfa antibodies.
Pri pediatričnih bolnikih, mlajših od 7 let, je bilo 0 od 7 moških bolnikov pozitivnih za protitelesa IgG proti agalzidazi alfa.
In paediatric patients >7 yrs of age, 1/16 male patients tested positive for IgG anti-agalsidase alfa antibodies during the study.
Med študijo je bil 1 od 16 moških pediatričnih bolnikov, starejših od 7 let, pozitiven za protitelesa IgG proti agalzidazi alfa.
In paediatric patients less than 10 years of age, the usual effective dose regimen is 100 mg/kg/day given in 2 doses daily; increasing the frequency above twice daily and/or the dose above 150 mg/kg/day does not improve the homocysteine-lowering effect.
Pri pediatričnih bolnikih, mlajših od 10 let, je običajna učinkovita shema odmerjanja 100 mg/kg/dan, dana v 2 dnevnih odmerkih; če dajemo zdravilo pogosteje kot dvakrat na dan ali če zvečamo odmerek nad 150 mg/kg/dan ali oboje, se učinek na znižanje homocisteina ne bo izboljšal.
In paediatric patients on dialysis (30% to 50% reduction in glomerular filtration rate) within age ranges of 5 to 11 years and 12 to 18 years, the mean weight-normalised CL/F was larger for younger paediatric patients (580 mL/h/kg) than for older paediatric patients (450 mL/h/kg) as compared with adults (287 mL/h/kg).
Pri otrocih na dializi (za 30 do 50 % zmanjšana glomerulna filtracija) je bil povprečni na telesno maso prilagojeni očistek CL/F večji pri mlajših otrocih (v starostni skupini od 5 do 11 let – 580 ml/h/kg) kot pri starejših (od 12 do 18 let – 450 ml/h/kg) v primerjavi z odraslimi (287 ml/h/kg).
In paediatric patients the half-life was slightly longer and the total clearance related to body weight slightly higher than in adult patients (see section 4.2).
Pri pediatričnih bolnikih je bil razpolovni čas nekoliko daljši in celotni očistek, glede na telesno maso, nekoliko višji kot pri odraslih bolnikih (glejte poglavje 4.2).
In paediatric patients the recommended haemoglobin concentration range is between 9.5 g/dl to 11 g/dl (5.9 to 6.8 mmol/l).
Pri pediatričnih bolnikih je priporočeni razpon koncentracije hemoglobina med 9,5 g/dl in 11 g/dl (med 5,9 in 6,8 mmol/l).
In paediatric patients who are at risk of aspiration, aged approximately 6 years and under, the hard capsules should be opened and the content sprinkled on food or liquid listed below.
Pri pediatričnih bolnikih do približno 6. leta starosti, pri katerih obstaja nevarnost aspiracije, je treba trde kapsule odpreti in vsebino stresti na spodaj navedeno hrano ali tekočino.
in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (7 ml/kg/month of packed red blood cells) aged 2 to 5 years,
pri pediatričnih bolnikih, ki imajo beta talasemijo major in preobremenitev z železom zaradi pogostih transfuzij krvi (7 ml/kg/mesec koncentriranih eritrocitov) in so stari od 2 do 5 let,
In paediatric patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Binocrit by the intravenous route is preferable.
Pri pediatričnih bolnikih s kronično ledvično odpovedjo, kjer je rutinsko na voljo intravenski dostop (bolniki na hemodializi), je zaželeno intravensko dajanje zdravila Binocrit.
In paediatric patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Epoetin alfa HEXAL by the intravenous route is preferable.
Pri pediatričnih bolnikih s kronično ledvično odpovedjo, kjer je rutinsko na voljo intravenski dostop (bolniki na hemodializi), je zaželeno intravensko dajanje zdravila Epoetin alfa HEXAL.
In paediatric patients with longer duration of current severe clinical TMA manifestation prior to eculizumab, there was TMA control with eculizumab treatment.
Pri pediatričnih bolnikih z daljšim trajanjem nedavne resne manifestacije trombotične mikroangiopatije (TMA) pred ekulizumabom je prišlo ob zdravljenju z ekulizumabom do nadzora TMA.
In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was 160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg.
Pediatrični bolniki z zmerno do hudo Crohnovo boleznijo so odvisno od njihove telesne mase (več ali manj kot 40 kg) dobivali odprt začetni odmerek adalimumaba 160/80 mg v 0. tednu in 80/40 mg v 2. tednu.
In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was 160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg.
Pediatrični bolniki z zmerno do hudo Crohnovo boleznijo so odvisno od njihove telesne mase (več ali manj kot 40 kg) dobivali odprt začetni odmerek adalimumaba 160/80 mg v 0.tednu in 80/40 mg v 2. tednu.
In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was 160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg.
Pediatrični bolniki z zmerno do hudo Crohnovo boleznijo so odvisno od njihove telesne mase (več ali manj od 40 kg) dobivali odprt začetni odmerek adalimumaba 160/80 mg v 0.tednu in 80/40 mg v 2. tednu.
In paediatric patients with renal dysfunction who are undergoing dialysis it is recommended following each dialysis treatment patients receive an additional dose of Viramune oral suspension or immediate-release tablets representing 50 % of the recommended daily dose of Viramune oral suspension or immediate-release tablets, which would help offset the effects of dialysis on nevirapine clearance.
Za otroke z ledvično disfunkcijo, ki se zdravijo z dializo, priporočajo po vsaki dializi dodaten odmerek zdravila Viramune peroralna suspenzija ali tablete s takojšnjim sproščanjem, in sicer še 50 % priporočenega dnevnega odmerka zdravila Viramune peroralna suspenzija ali tablete s takojšnjim sproščanjem, kar pomaga izničiti učinek dialize na nevirapinov očistek.
In paediatric patients with shorter duration of current severe clinical thrombotic microangiopathy (TMA) manifestation prior to eculizumab, there was TMA control and improvement of renal function with eculizumab treatment (Table 10).
Pri pediatričnih bolnikih s krajšim trajanjem nedavne resne manifestacije trombotične mikroangiopatije (TMA) pred ekulizumabom je prišlo ob zdravljenju z ekulizumabom do nadzora TMA in izboljšanja ledvične funkcije (preglednica 10).
In paediatric patients without previous exposure to anthracyclines or cardiac radiation, the most common adverse reactions were GI toxicity, neutropenia, fatigue and ALT elevation.
Pri pediatričnih bolnikih brez predhodne izpostavljenosti antraciklinom ali obsevanju srca, so bili najpogostejši neželeni učinki gastrointestinalna toksičnost, nevtropenija, utrujenost in zvišanje ravni alanin-aminotransferaze (ALT).
In paediatric PNH and aHUS patients with body weight below 40 kg, the Soliris dosing regimen consists of:
Pri pediatričnih bolnikih s PNH in z aHUS s telesno maso manj kot 40 kg je shema odmerjanja zdravila Soliris sestavljena iz:
In paediatric population
Pediatrična populacija
In Paget’s disease, Aclasta was more effective than risedronate.
Pri Pagetovi bolezni je bilo zdravilo Aclasta učinkovitejše od rizedronata.
In Paget’s disease, bone remodelling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal.
Pri Pagetovi bolezni je kostna pregradnja prehitra, nova kostnina pa se tvori nepravilno, zato je šibkejša od normalne.
In Paget’s disease, the bone breaks down more quickly, and when it grows back, it is weaker than normal.
Pri Pagetovi bolezni se kost hitreje zlomi, ko pa se zaraste, je šibkejša kot običajno.
In Paget’s disease, the bone breaks down more quickly, and when it grows back, it is weaker than normal.
Pri Pagetovi bolezni se kostnina hitreje razgrajuje, ko pa kostno tkivo ponovno zraste, je šibkejše kot običajno.
In Paget’s disease, the recommended dosage is 100 IU per day given subcutaneously or intramuscularly, however, a minimum dose of 50 IU three times a week is also effective.
Pri Pagetovi bolezni je priporočeni odmerek 100 i.e. dnevno, ki se daje podkožno ali intramuskularno, vendar je učinkovit tudi minimalni odmerek 50 i.e. trikrat tedensko.
In PAH there is severe narrowing of the arteries of the lungs.
Za PAH je značilno hudo zoženje pljučnih arterij.
In PAH, Stayveer has been studied in four main studies: two in a total of 245 adults with class III or IV disease that was either primary or caused by scleroderma, one in 54 adults with class III PAH that was associated with congenital heart defects, and one in 185 patients with class II disease.
Koristi zdravila Stayveer pri pljučni arterijski hipertenziji so proučevali v štirih glavnih študijah: v dveh s skupno 245 odraslimi s pljučno arterijsko hipertenzijo razreda III ali IV, ki je bila bodisi primarna bodisi posledica skleroderme, v eni s 54 odraslimi s pljučno arterijsko hipertenzijo razreda III, ki je bila povezana s kongenitalnimi srčnimi boleznimi, in v eni s 185 bolniki s pljučno arterijsko hipertenzijo razreda II.
In PAH, the most common side effects with Stayveer (which may affect more than 1 patient in 10) are headache and abnormal results of tests carried out to check the liver.
Pri bolnikih s pljučno arterijsko hipertenzijo so najpogostejši neželeni učinki zdravila Stayveer (ki lahko prizadenejo več kot 1 bolnika od 10) glavobol in nenormalni rezultati testov delovanja jeter.
In PAH, Tracleer film-coated tablets have been studied in four main studies: two in a total of 245 adults with class III or IV disease that was either primary or caused by scleroderma, one in 54 adults with class III PAH that was associated with congenital heart defects, and one in 185 patients with class II disease.
Pri PAH so bile filmsko obložene tablete Tracleer proučevane v štirih glavnih študijah: v dveh študijah s skupno 245 odraslimi bolniki z boleznijo III. ali IV. funkcijskega razreda, ki je bila bodisi primarna ali posledica skleroderme, eni študiji s 54 odraslimi bolniki s PAH III. funkcijskega razreda, povezano s prirojeno srčno napako, ter eni študiji s 185 bolniki z boleznijo II. funkcijskega razreda.
In pancreatic cancer, Tarceva in combination with gemcitabine has been studied in 569 patients with pancreatic cancer that was advanced, unresectable (that cannot be removed by surgery) or metastatic.
Pri raku trebušne slinavke so zdravilo Tarceva v kombinaciji z gemcitabinom proučevali pri 569 bolnikih z napredovalim, neoperabilnim (ki ga ni mogoče odstraniti s kirurškim posegom) ali metastatskim rakom trebušne slinavke.
In parentheses is the adverse reaction incidence (% of patients) in rasagiline vs. placebo, respectively.
V oklepaju je incidenca neželenih učinkov (% pacientov) pri razagilinu v primerjavi s placebom.
In parentheses is the adverse reaction incidence (% of patients) in rasagiline vs. placebo, respectively.
V oklepaju je incidenca neželenih učinkov (% pacientov) pri razagilinu vs. placebo.
In Parkinson’s disease, Leganto has been compared with placebo (a dummy treatment) in four studies involving 830 patients with early-stage disease and 842 patients with advanced disease.
Pri zdravljenju Parkinsonove bolezni so zdravilo Leganto primerjali s placebom (zdravilom brez zdravilne učinkovine) v štirih študijah, v katerih je sodelovalo 830 bolnikov v zgodnjem stadiju bolezni in 842 bolnikov z napredovalo boleznijo.
In Parkinson’s disease, Mirapexin immediate-release tablets have been studied in five main studies.
Pri Parkinsonovi bolezni so tablete Mirapexin s takojšnjim sproščanjem proučevali v petih glavnih študijah.
In Parkinson’s disease, Neupro has been compared with placebo (a dummy treatment) in four studies involving 830 patients with early-stage disease and 842 patients with advanced disease.
Pri zdravljenju Parkinsonove bolezni so zdravilo Neupro primerjali s placebom (zdravilom brez zdravilne učinkovine) v štirih študijah, v katere je bilo skupaj vključenih 830 bolnikov v zgodnji fazi bolezni in 842 bolnikov z napredovalo boleznijo.
In Parkinson’s disease, Sifrol immediate-release tablets have been studied in five main studies.
Pri Parkinsonovi bolezni so tablete Sifrol s takojšnjim sproščanjem proučevali v petih glavnih študijah.
In part 1 of study 5, the mean FEV1 percent predicted at baseline in placebo-treated patients was 79.3% while in ivacaftor-treated patients this value was 76.4%.
Zvišanje transaminaz se je pojavilo pri 12,8 % bolnikov, zdravljenih z ivakaftorjem, in pri 11,5 % bolnikov, ki so prejemali placebo.
In Part 1, eligible patients ≥ 30 kg received tocilizumab at 8 mg/kg IV every 4 weeks for 4 doses.
V I. delu so primerni bolniki s telesno maso ≥ 30 kg prejeli 4 odmerke po 8 mg/kg tocilizumaba i.v. vsake 4 tedne.
In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV1 following 16 weeks (patients randomised to the ivacaftor/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%).
Neprekinjeno zdravljenje z ivakaftorjem je trajalo 24 tednov pri bolnikih, randomiziranih na zaporedje zdravljenja placebo/ivakaftor iz prvega dela, in 16 tednov pri bolnikih, randomiziranih na zaporedje zdravljenja ivakaftor/placebo iz prvega dela.
In Part A and Part B, physician’s and patient’s global assessment of disease activity and patients’ assessment of the degree of limitation of their daily activities due to their disease were significantly improved for patients treated with rilonacept compared with those on placebo.
V delu A in delu B se je zdravnikova in bolnikova globalna ocena aktivnosti bolezni in bolnikova ocena stopnje omejitve dnevnih aktivnosti zaradi bolezni signifikantno izboljšala pri bolnikih, zdravljenih z rilonaceptom, v primerjavi s tistimi na placebu.
In part I (open label) 177 patients were enrolled and received 4 mg/kg (up to 300 mg) Ilaris administered every 4 weeks for up to 32 weeks.
V 1. obdobju (odprto zdravljenje) je bilo vključenih 177 bolnikov, ki so prejemali odmerke 4 mg/kg (največ 300 mg) zdravila Ilaris vsake 4 tedne do 32 tednov.
In Part II, patients were randomized to tocilizumab (same dose received in Part I) or placebo in a 1:1 ratio, stratified by concurrent MTX use and concurrent corticosteroid use.
V II. delu so bili bolniki randomizirani v skupino, ki je prejemala tocilizumab (enak odmerek kot v I. fazi) ali placebo v razmerju 1:1, stratifikacijo so naredili glede na sočasno uporabo metotreksata in kortikosteroidov.
In Part II, treatment assignment was double-blind with respect to Avastin.
V II. delu je bila določitev zdravljenja glede uporabe zdravila Avastin dvojno slepa.
in partial-onset seizures, it has been studied in three main studies in a total of 904 patients aged 16 years and over.
pri napadih parcialnega izvora, in sicer v treh glavnih študijah pri skupno 904 bolnikih, starih 16 let in več.
In particular let your doctor know if you are taking: treatments containing ketoconazole for fungal infections, macrolide antibiotics like clarithromycin, or diltiazem as a treatment for high blood pressure and chest pain.
Zdravniku še zlasti povejte, če jemljete: zdravilo, ki vsebuje ketokonazol za glivične okužbe, makrolidne antibiotike, kot je klaritromicin, ali diltiazem za zdravljenje visokega krvnega tlaka in bolečin v prsnem košu.
In particular please tell your doctor if you are taking any of the following:
Zdravniku še zlasti povejte, če jemljete kaj od naslednjega:
In particular tell your doctor if you are taking:
Zlasti povejte zdravniku, če jemljete:
In particular tell your doctor or nurse if you are taking any of the following medicines:
Posebej pomembno je, da obvestite zdravnika ali medicinsko sestro, če jemljete naslednja zdravila:
In particular tell your doctor or pharmacist if you are taking any of the following medicines (taking Cholib with any of these medicines can increase the risk of muscle problems):
Posebej pomembno je, da obvestite zdravnika ali farmacevta, če jemljete katero koli od naslednjih zdravil (jemanje zdravila Cholib s katerim koli od teh zdravil lahko poveča tveganje za težave
In particular tell your doctor or pharmacist if you are taking any of the following:
Še posebej opozorite zdravnika ali farmacevta, če jemljete kar koli od naslednjega:
In particular tell your doctor or pharmacist if you are taking any of the following:
Še posebno pomembno je, da svojemu zdravniku poveste, če jemljete katero od naslednjih zdravil:
In particular you should tell your doctor if you are using: levodopa (used to treat Parkinson’s disease)
Zdravniku povejte še zlasti, če uporabljate: levodopo (uporablja se za zdravljenje Parkinsonove bolezni),
In particular, although no adverse effects were noted in reproduction studies at human exposure levels, the animal exposures are not sufficient to make an adequate risk assessment in man.
Še zlasti je pomembno, da tveganja za vpliv na sposobnost razmnoževanja pri človeku glede na študije pri živalih ni mogoče zadovoljivo oceniti, čeprav neželenih učinkov med študijami na živalih pri stopnjah izpostavljenosti, ki so bile podobne stopnjam klinične izpostavljenosti, niso opazili.
In particular, chronic asymptomatic carriers should be identified and treated before vaccination, with substances that do not compromise immunological responsiveness.
Odkrivati je treba kronične asimptomatske nosilce in jih pred cepljenjem zdraviti z zdravili, ki ne vplivajo na imunski odgovor.
In particular, do not have this medicine and tell your doctor if: you are using the medicine called heparin to treat blood clots
Zlasti ne uporabljajte tega zdravila in zdravniku povejte, če: za zdravljenje krvnih strdkov uporabljate zdravilo, imenovano heparin.
In particular, do not take Sovaldi if you are taking any of the following medicines:
Zdravila Sovaldi še zlasti ne jemljite, če uporabljate katero od naslednjih zdravil:
In particular, do not take this medicine and tell your doctor or pharmacist if you are taking any of the following medicines:
Še zlasti ne jemljite tega zdravila in obvestite svojega zdravnika ali farmacevta, če jemljete katero od naslednjih zdravil:
In particular, do not take this medicine and tell your doctor or pharmacist if you are taking any of the following medicines:
Še zlasti ne smete uporabljati tega zdravila in obvestite svojega zdravnika ali farmacevta, če jemljete katero od naslednjih zdravil:
In particular, do not take Victrelis if you are taking any of the following medicines:
Še zlasti ne vzemite zdravila Victrelis, če jemljete katero od naslednjih zdravil:
In particular, if you are following a diabetic weight control diet, continue with this while you are taking Eucreas.
Še posebno če se držite diete za uravnavanje telesne mase za diabetike, z dieto nadaljujte tudi v obdobju jemanja zdravila Eucreas.
In particular, if you are taking a medicine containing the active substance ciclosporin to suppress your immune system after a kidney transplant, your doctor may order special blood tests to measure ciclosporin levels while you are taking Retacrit.
V primeru, da jemljete zdravilo, ki vsebuje zdravilno učinkovino ciklosporin, s katerim se po presaditvi ledvic zavira imunski sistem, vam bo zdravnik morda predpisal posebne teste krvi, s katerimi se med jemanjem zdravila Retacrit meri koncentracija ciklosporina.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co- primary endpoint (CV death, MI, stroke or refractory ischaemia).
Zlasti post hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčno- žilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Zlasti post hoc analiza podatkov 2.172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčno- žilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).